Stock Market & Financial News

Loading...
Buy, Hold or Sell UUUU Stock After Its Massive 176% Six-Month Run?

Buy, Hold or Sell UUUU Stock After Its Massive 176% Six-Month Run?

Energy Fuels' explosive rally, surging uranium output and rapid rare earth gains spotlight big momentum, alongside rising costs and valuation risks.

Zacks | 1 day ago

Can Coca-Cola's Innovation Pipeline Outrun Health-Conscious Shifts?

KO drives growth with bold innovation, expanding beyond sodas into energy drinks, coffees and low-sugar beverages globally.

Zacks | 1 day ago

Lear: Becoming Bullish On Better Prospects (Rating Upgrade)

I raise my rating for Lear Corporation to "Buy," following my evaluation of its financial outlook. LEA anticipates that its 4Q25 performance will be at the upper end of management guidance; it also expects a return to positive topline and bottom-line expansion next year. There are multiple financial improvement drivers, such an absence of one-offs, reshoring trends, Chinese OEM penetration, and automation-driven expense reductions.

Seekingalpha | 1 day ago

Streaming Wars Continue as Paramount Takes Final Swing

The unavoidable noise surrounding Netflix's ( NFLX ) expansive, $72 billion buyout of Warner Bros Discovery (WBD) is shaking up Wall Street today.

Schaeffersresearch | 1 day ago
IMAX price target boosted as Investor Day boosts analyst optimism

IMAX price target boosted as Investor Day boosts analyst optimism

IMAX Corp (NYSE:IMAX) received a price target upgrade from Wedbush analysts following the company's 2025 Investor Day, with the firm raising its price target to $46 from $39 and maintaining an 'Outperform' rating. IMAX shares jumped more than 8% following the event, trading at about $38 in the early afternoon on Monday.

Proactiveinvestors | 1 day ago
Oracle: Low Enough Expectations For Q2 Upside (Rating Upgrade)

Oracle: Low Enough Expectations For Q2 Upside (Rating Upgrade)

Oracle Corporation is entering Q2 earnings with low expectations and much negativity priced in, and I think that sets the stage for a potential upside surprise. Oracle's relative underperformance versus AI and cloud peers reflects a valuation and narrative reset, not a deterioration in fundamentals. Oracle's infrastructure-critical role in AI platforms and enterprise adoption supports a less cyclical, less speculative growth profile.

Seekingalpha | 1 day ago
UBS Group AG Plans 10,000 Job Cuts: Will it Boost Efficiency?

UBS Group AG Plans 10,000 Job Cuts: Will it Boost Efficiency?

Can UBS's plan to cut 10,000 jobs by 2027 sharpen efficiency as its Credit Suisse integration deepens? Let us find out.

Zacks | 1 day ago
Commercial Metals Stock Hits 52-Week High: What's Driving It?

Commercial Metals Stock Hits 52-Week High: What's Driving It?

CMC hits a 52-week high as strong Q4 results and the closing of its CP&P acquisition boost momentum and growth expectations.

Zacks | 1 day ago
USAR Enhances Rare Earth Supply Chain With LCM's Partnership Deal

USAR Enhances Rare Earth Supply Chain With LCM's Partnership Deal

USA Rare Earth deepens its mine-to-magnet strategy as LCM's new supply deal boosts rare earth security across the United States and Europe.

Zacks | 1 day ago
Earnings Estimates Rising for AvePoint (AVPT): Will It Gain?

Earnings Estimates Rising for AvePoint (AVPT): Will It Gain?

AvePoint, Inc. (AVPT) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Zacks | 1 day ago

Earnings Estimates Moving Higher for Certara (CERT): Time to Buy?

Certara, Inc. (CERT) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Zacks | 1 day ago

Large-Cap Anxiety? Leverage Midcap Marvels With This ETF

Traders worried about large-cap stocks hitting peak valuations may want to step into the midcap arena. Long- and short-term traders can also take advantage of future upside if the market environment shifts in favor of these companies.

Etftrends | 1 day ago

Box: Cheap FCF Multiples Amid AI-Driven Backlog Growth

Box remains a value-oriented, underappreciated enterprise software stock despite AI-driven market narratives. BOX trades at attractive valuation multiples—3.5x EV/FY27 revenue and 12.5x EV/FY27 FCF—while generating robust free cash flow. Management raised FY26 guidance, projecting $1.175 billion in revenue and $1.28 pro forma EPS, with double-digit billings and RPO growth.

Seekingalpha | 1 day ago

Bulls Bet on Alphabet Stock as AI Race Tightens

Alphabet Inc (NASDAQ:GOOGL) took the AI spotlight in late November, amid reports it's in talks with  Meta Platforms (META) to produce custom chips for its data centers.

Schaeffersresearch | 1 day ago

Here's How Lazard's Advisory Push Positions It for 2030 Growth

LAZ accelerates its advisory expansion with senior hires, private-capital growth and global reach to drive revenues and productivity into 2030.

Zacks | 1 day ago

The Trade Desk faces rising AI competition, Wedbush flags

Wedbush Securities has lowered its 12-month price target for The Trade Desk Inc (NASDAQ:TTD) to $40 from $50, citing growing structural disadvantages in an increasingly AI-driven advertising landscape. Analysts at Wedbush said The Trade Desk should continue to see topline growth, supported by the ongoing migration of linear advertisers to connected TV (CTV) and digital platforms, deeper integration across media channels, and the company's content-agnostic approach.

Proactiveinvestors | 1 day ago

US to open up exports of Nvidia H200 chips to China, Semafor reports

The U.S. Commerce Department will soon allow Nvidia Corp's H200 chip to be exported to China, Semafor news outlet reported on Monday, citing a person with knowledge of the plan.

Reuters | 1 day ago

Lumentum Holdings Inc. (LITE) Presents at Raymond James TMT & Consumer Conference Transcript

Lumentum Holdings Inc. (LITE) Presents at Raymond James TMT & Consumer Conference Transcript

Seekingalpha | 1 day ago

Terreno Hyattsville Property Buy: What it Means for Growth Plans?

TRNO's $50M Hyattsville buy boosts its logistics presence and supports a long-term growth strategy centered on high-barrier industrial markets.

Zacks | 1 day ago

Virtus Pushes Into Private Markets With Majority Stake in Keystone

VRTS moves into private markets with a majority stake in Keystone to add asset-backed lending capabilities.

Zacks | 1 day ago

Robinhood Enters Indonesia Via Buyouts: A Catalyst for APAC Expansion?

HOOD enters Indonesia with two buyouts, tapping into a young, mobile-first market to fuel APAC expansion.

Zacks | 1 day ago

Same-Day Delivery Emerges as Target's Biggest Digital Growth Driver

TGT's same-day delivery is rapidly becoming its top traffic driver, boosting digital sales and reshaping customer convenience.

Zacks | 1 day ago

Sally Beauty (SBH) Upgraded to Buy: Here's Why

Sally Beauty (SBH) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks | 1 day ago

What Makes ZTO Express (Cayman) Inc. (ZTO) a Strong Momentum Stock: Buy Now?

Does ZTO Express (Cayman) Inc. (ZTO) have what it takes to be a top stock pick for momentum investors? Let's find out.

Zacks | 1 day ago

PDS Biotechnology (PDSB) Upgraded to Buy: Here's Why

PDS Biotechnology (PDSB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks | 1 day ago

Talos Energy (TALO) is a Great Momentum Stock: Should You Buy?

Does Talos Energy (TALO) have what it takes to be a top stock pick for momentum investors? Let's find out.

Zacks | 1 day ago

Rapport Therapeutics, Inc. (RAPP) Is Up 9.03% in One Week: What You Should Know

Does Rapport Therapeutics, Inc. (RAPP) have what it takes to be a top stock pick for momentum investors? Let's find out.

Zacks | 1 day ago

Theravance Biopharma (TBPH) is a Great Momentum Stock: Should You Buy?

Does Theravance Biopharma (TBPH) have what it takes to be a top stock pick for momentum investors? Let's find out.

Zacks | 1 day ago

CorMedix (CRMD) Upgraded to Strong Buy: Here's What You Should Know

CorMedix (CRMD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Zacks | 1 day ago

Arcutis Biotherapeutics: The Earnings Inflection Has Arrived

Arcutis Biotherapeutics has transitioned to profitability, driven by Zoryve's strong sales growth and market acceptance. Management projects Zoryve peak sales of $2.6B–$3.5B, far above Wall Street's $1.69B estimate, supporting a bullish outlook. ARQT's Q3 net income reached $7.4M, with cash flow break-even now expected in Q4, de-risking the investment case.

Seekingalpha | 1 day ago
Load More
Loading...